Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Tags:
OTC Drugs

Sunscreen Nanoparticles Impact On Microbes May Signal Nano-Eco Conflict

This article was originally published in The Tan Sheet

  • News

Executive Summary

Research on the impact of nano-sized metals on microorganisms suggests personal-care and other consumer products with such particles could harm the environment

You may also be interested in...



Ivy Nanoparticles In Sunscreens Safer, Stickier Than Titanium Oxide - Study

Isolated organic nanoparticles from English ivy offer performance advantages and a superior safety profile compared with nano-sized titanium dioxide, a common sunscreen ingredient, researchers say

Ivy Nanoparticles In Sunscreens Safer, Stickier Than Titanium Oxide - Study

Isolated organic nanoparticles from English ivy offer performance advantages and a superior safety profile compared with nano-sized titanium dioxide, a common sunscreen ingredient, researchers say

Ivy Nanoparticles In Sunscreens Safer, Stickier Than Titanium Oxide - Study

Isolated organic nanoparticles from English ivy offer performance advantages and a superior safety profile compared with nano-sized titanium dioxide, a common sunscreen ingredient, researchers say

Table

View full table

Related Content

Pink Sheet

Topics

Tags:
OTC Drugs
Latest Headlines

Patent Office Issues Proposed Rule For Rarely Successful Director Review Requests

Medicare Spending Forecast For Leqembi Reflects CMS Angst About Alzheimer’s Drug Costs

US FDA Drugs Center Launches Clinical Trial Innovation Hub With Demonstration Projects

EMA Releases Guidance On How & When Its RWE Generation Service Can Be Used

See All
UsernamePublicRestriction

Register

PS102832

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By